At the news
? MIXEDIMPACT 5/10 CLUSTER filed Feb 19, 2026 at 19:00 ET
A cluster of insider transactions at Ocular Therapeutix (OCUL) shows mixed activity: one significant open-market purchase by external investor Richard L. Lindstrom for $461K, alongside coordinated open-market sales by five executives totaling $256K. The selling executives include the Chief Development Officer, Chief Scientific Officer, Chief Strategy Officer, Chief Medical Officer, and Pravin Dugel (role unspecified), all selling near the same price point.
- Richard L. Lindstrom purchased 60,229 shares at $7.66 for $461,354.14 on February 20, 2026.
- Five insiders sold a combined 31,192 shares across February 20 and 23, 2026, for $256,374.36 in total.
- Selling insiders include four C-suite executives: Peter Kaiser (CDO), Jeffrey Heier (CSO), Sanjay Nayak (CSO), and Nadia Waheed (CMO), plus Pravin Dugel.
- All transactions were open-market trades; no derivative exercises or grants involved.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access